Cenobamate
Anticonvulsant drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Cenobamate?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Cenobamate, sold under the brand names Xcopri (US) and Ontozry (EU), is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults. It is taken by mouth.[3][7][8]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Xcopri, Ontozry |
Other names | YKP3089 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620021 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ≥88% |
Protein binding | 60% |
Metabolism | Mainly glucuronidation via UGT2B7 |
Elimination half-life | 50–60 hours |
Excretion | Mainly via urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
PubChem SID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C10H10ClN5O2 |
Molar mass | 267.67 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
Cenobamate was approved for medical use in the United States in November 2019[3][7][8][9] and placed in Schedule V of the Controlled Substances Act in March 2020.[10] Cenobamate was approved for medical use in the European Union in March 2021 [5] and approved for use in Canada in June 2023.[11]